A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose-Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects With Symptomatic Carcinoid Syndrome
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Telotristat etiprate (Primary)
- Indications Malignant carcinoid syndrome
- Focus Adverse reactions
- Sponsors Lexicon Pharmaceuticals
- 12 Sep 2017 Results of pooled analysis of 5 trials (NCT02026063, NCT02063659, NCT01677910, NCT01104415, NCT00853047) presented at the 42nd European Society for Medical Oncology Congress
- 24 Feb 2013 New trial record